stockrowTeva Pharmaceutical Industries Ltd.
TEVA Healthcare Drug Manufacturers Specialty & Generic
Teva Pharmaceutical Industries Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17.3 billion, up 4.32% from fiscal 2024.
- Revenue
- −1.90%
- EPS
- −47.2%
- Free cash flow
- −30.3%
- Total debt
- −0.43%
Quarter to September 2026, against a year earlier
Follow TEVA
Alert me
Teva Pharmaceutical Industries Ltd. (TEVA) Price to free cash flow
As of 5 November 2026, Teva Pharmaceutical Industries Ltd. (TEVA) trades at a price to free cash flow of 36.6×. Over the past ten years it has ranged from 2.6× (September 2017) to 122× (April 2021); the current reading is higher than 93% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 16.3× and above the Healthcare sector median of 21.1×.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 30.2× | (3.94%) |
| FY2024 | 31.5× | 139.88% |
| FY2023 | 13.1× | 37.68% |
| FY2022 | 9.5× | (45.31%) |
| FY2021 | 17.4× | 16.27% |
| FY2020 | 15.0× | (20.66%) |
| FY2019 | 18.9× | 222.16% |
| FY2018 | 5.9× | 85.76% |
| FY2017 | 3.2× | (44.21%) |
| FY2016 | 5.7× | (46.63%) |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Sep 2026 | 34.8× | 23.41% |
| Jun 2026 | 28.2× | (0.40%) |
| Mar 2026 | 28.3× | (6.44%) |
| Dec 2025 | 30.2× | (19.62%) |
| 43 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| TAK Takeda Pharmaceutical Co. compare | 8.4× |
| HLN Haleon PLC Sponsored ADR compare | 9.2× |
| VTRS Viatris Inc. compare | 10.7× |
| ZTS Zoetis Inc. compare | 14.7× |
| NBIX Neurocrine Biosciences, Inc. compare | 15.7× |
| UTHR United Therapeutics Corporation compare | 28.0× |
| ELAN Elanco Animal Health Incorporated compare | 33.2× |
| TEVA Teva Pharmaceutical Industries Ltd. | 36.6× |
| RDY Dr. Reddy's Laboratories Ltd compare | 126× |
| Drug Manufacturers Specialty & Generic industry median | 16.3× |
| Healthcare sector median | 21.1× |
| Market median | 14.1× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on TEVA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement